Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005;106(8):2841-8. doi:10.1182/blood-2005-02-0488
Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321-30. doi:10.1016/j.ccr.2006.09.005
Sboner A, Demichelis F, Calza S, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010;3:8. doi:10.1186/1755-8794-3-8
Van Allen EM, W Y Lui V, Egloff AM, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015;1(2):238-44. doi:10.1001/jamaoncol.2015.34
Stewart ML, Tamayo P, Wilson AJ, et al. KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Cancer Res. 2015;75(14):2897-906. doi:10.1158/0008-5472.CAN-14-2860
Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016;29(4):574-86. doi:10.1016/j.ccell.2016.03.008
Kim W, Le TM, Wei L, et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A. 2016;113(15):4027-32. doi:10.1073/pnas.1524212113
Petrovics G, Li H, Stümpel T, et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine. 2015;2(12):1957-64. doi:10.1016/j.ebiom.2015.10.028
Diamandis P, Ferrer-Luna R, Huang RY, et al. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016;11:13. doi:10.1186/s13000-016-0455-9